GlassScriptPhysician profile
Russell John Young
NPI 1144285529
$8,488.48
in general payments reported to CMS, 2019-2025
26 companies · $17.50 in 2025
The $17.50 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $1,605 · 2021: $1,277 · 2022: $1,979 · 2023: $1,828 · 2024: $919 · 2025: $17.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,593.27 |
| Education | $171.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,581.57 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,472.61 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Barco, INC. | $956.20 | 2020 | |
| Abiomed | $777.44 | 2021-2022 | |
| Lilly USA, LLC | $434.83 | 2019-2024 | Olumiant, Taltz |
| Genzyme Corporation | $420.20 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $273.94 | 2019-2023 | Ilumya |
| Novartis Pharmaceuticals Corporation | $249.69 | 2019-2024 | |
| Amgen INC. | $245.71 | 2020-2024 | Otezla |
| Janssen Scientific Affairs, LLC | $229.40 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $196.94 | 2019-2024 | Dupixent |
| Ucb, INC. | $103.22 | 2021-2024 | Bimzelx, Cimzia |
| Siemens Medical Solutions USA, INC. | $102.93 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.98 | 2022-2023 | Spevigo |
| Celgene Corporation | $45.98 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.54 | 2019 | |
| Genentech USA, INC. | $38.19 | 2020-2021 | |
| Strata Skin Sciences, INC. | $36.60 | 2019 | |
| Arcutis Biotherapeutics, INC. | $36.59 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $33.69 | 2023 | Sotyktu |
| Pfizer INC. | $33.61 | 2019 | |
| Dermira, INC. | $22.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $20.97 | 2021 | |
| Biofrontera INC. | $20.72 | 2019 | |
| Leo Pharma INC. | $17.17 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.76 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.